glp 1 triple agonist Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Upcoming wave of hormone-based therapies

Glucagon-like peptide-1 (GLP-1) is an incretin hormone, one of several gut-derived peptides secreted in response to nutrient intake that promote insulin release

Studies in animals with GIP knockout genes have shown different results depending on the deleted exon

Journal of diabetes research

Recently, three new axes have been identified, emphasizing the role of the kidney in this picture (22): The ACE2/ANG(1-7)/Mas receptor pathway (23, 24): Ang-(1-7) binds to the G protein-coupled receptor Mas, which is expressed in renal proximal tubular cells, afferent arterioles, cardiac myocytes, and neuronal cells

So you know, our powers that be are working to try to see what they can do to help cover some of that cost [of GLP1s], which is something that our employees liked. Human Resource Representative, large manufacturer We were covering [GLP-1 agonists for weight loss] and they tripled our cost